Technical analysis for nvax

Here is the technical analysis for Novavax (NVAX) as of July 12, 2024:

1. RSI: The Relative Strength Index (RSI) for NVAX is at 59.06, which is near the midpoint of the 30-70 range. This suggests that the stock is neither overbought nor oversold, indicating a balanced buying pressure.

2. MACD: The Moving Average Convergence Divergence (MACD) is -0.3, indicating a bearish momentum as the MACD is below the signal line. This could imply a potential downward trend in the short term.

3. KDJ: The KDJ indicator shows a value of 71.43, which is in the overbought territory. This suggests that the stock may be due for a pullback or consolidation in the short term.

4. Support and Resistance Levels: The support level is at $13, and the resistance level is at $13.86. These levels can act as psychological barriers, where the stock may face selling pressure above the resistance and buying support below the support.

5. Moving Averages: The 5-Day Moving Average is $12.38, the 10-Day Moving Average is $12.47, and the 20-Day Moving Average is $13.2. The stock is trading above the 5-Day and 10-Day Moving Averages but below the 20-Day Moving Average, indicating a short-term upward trend but a potential need to consolidate or correct.

6. Fibonacci Retracement: The 0.382 Fibonacci Retracement is at $8.2, and the 0.618 Fibonacci Retracement is at $10.3. These levels can act as potential support and resistance levels, respectively, based on the stock's performance over the past year.

In conclusion, NVAX shows signs of a balanced buying pressure but with potential bearish momentum and overbought conditions. The stock is trading above short-term moving averages but below the 20-Day Moving Average, suggesting a need for consolidation. Investors should monitor the stock's performance around the support and resistance levels and the moving averages for further insights into its short-term direction.